25 Recruiting Studies Using Dabrafenib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Dabrafenib
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
📍 M D Anderson Cancer Center — Houston, Texas
Stage IIIB Cutaneous Melanoma AJCC v7
View Study & Checklist ➔PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Thyroid Cancer
View Study & Checklist ➔Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
📍 UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
Clinical Stage IV Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
📍 Stanford School of Medicine — Stanford, California
Thyroid Gland Anaplastic Carcinoma
View Study & Checklist ➔Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Metastatic Melanoma
View Study & Checklist ➔Pediatric Long-Term Follow-up and Rollover Study
📍 Phoenix Children s Hospital — Phoenix, Arizona
Diffuse Astrocytoma
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
📍 Northwestern University Med School — Chicago, Illinois
Differentiated Thyroid Cancer (DTC)
View Study & Checklist ➔Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Anaplastic Thyroid Cancer
View Study & Checklist ➔A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
📍 Phoenix Children's Hospital — Phoenix, Arizona
Low Grade Glioma (LGG) of Brain With BRAF Aberration
View Study & Checklist ➔Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Stage III Cutaneous Melanoma AJCC v7
View Study & Checklist ➔Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Clinical Stage III Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Clinical Stage III Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Anaplastic Astrocytoma
View Study & Checklist ➔Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Metastatic Thyroid Gland Carcinoma
View Study & Checklist ➔A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Malignant Neoplasm in the Brain
View Study & Checklist ➔Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
📍 University of Alabama at Birmingham — Birmingham, Alabama
BRAF V600 Mutation
View Study & Checklist ➔Dabrafenib and/or Trametinib Rollover Study
📍 Honor Health Research Institute — Scottsdale, Arizona
Melanoma
View Study & Checklist ➔Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
📍 University of Iowa — Iowa City, Iowa
Metastatic Melanoma
View Study & Checklist ➔Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Refractory Differentiated Thyroid Gland Carcinoma
View Study & Checklist ➔MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
📍 Children's National Hospital — Washington D.C., District of Columbia
Low Grade Glioma
View Study & Checklist ➔TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
📍 University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama
Lymphoma, Non-Hodgkin
View Study & Checklist ➔Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
📍 City of Hope Medical Center — Duarte, California
BRAF NP_004324.2:p.V600E
View Study & Checklist ➔